

ATAHC

<p>STUDY TITLE:</p>	<p>Australian Trial in Acute Hepatitis C (ATAHC)</p> <p>A prospective non-randomised dual arm longitudinal cohort of newly acquired hepatitis C infection into which participants will be enrolled and then followed at 3 monthly intervals over a 3 year period.</p> <p>All participants will be offered a 24 week course of Pegylated interferon alfa 2a (the name of the medication that will be used) which will be commenced within 12 weeks of screening. Participants co-infected with HIV will use both Pegylated interferon alfa 2a and Ribavirin for 24 weeks.</p>
<p>STUDY OBJECTIVE:</p>	<p>The main purposes of the study are:</p> <ul style="list-style-type: none"> • To enrol and follow-up a large group of people with acute hepatitis C infection to examine why some people naturally clear hepatitis C and some don't. • To examine how many people become re-infected after having cleared hepatitis C and to look at why this happened. <p>The study will also offer everyone taking part the option of undergoing a 6 month course of Pegylated –interferon as treatment for hepatitis C. The purpose of this part of the study is:</p> <ul style="list-style-type: none"> • To examine whether treatment is effective in clearing the virus.
<p>STUDY DESIGN:</p>	<p>All participants will be enrolled and followed for a period of 3 years.</p>
<p>STUDY DRUGS:</p>	<p>Pegasys: Pegylated interferon alfa 2a Ribavirin</p>
<p>STUDY COMPLETION DATE:</p>	<p>Recruitment stop date: 30th July 2007 (except three sites highlighted below, which will stop recruitment on 30th Nov 2007) Study closure date: December 2008</p>
<p>IS THE STUDY OPEN TO ENROLLMENT?:</p>	<p>Yes</p> <p>To enter the study you will need to be 16 years of age or older and have newly acquired Hepatitis C infection. Newly acquired hepatitis C means a positive hepatitis C antibody test in the last 6 months <i>PLUS</i> a negative</p>

	hepatitis C antibody test 2 years before this OR acute hepatitis (jaundice- yellow eyes and skin) 12 months before the positive antibody hepatitis C result.
NUMBER OF PATIENTS ENROLLED/TARGET ENROLLMENT:	Currently 146 people are enrolled. The study aims to recruit 240 people
SPONSOR:	The study is sponsored by the National Institutes of Drug Abuse, a division of the National Institutes of Health, USA
PARTICIPATING SITES:	<p>NSW St Vincent's Hospital Royal Prince Alfred Hospital Westmead Hospital John Hunter Hospital Nepean Hospital Kirketon Road Centre 407 Bourke Street Holdsworth House</p> <p>VIC Burnet Institute Alfred Hospital Royal Melbourne Hospital St Vincent's Hospital Monash Medical Centre The Austin Hospital The Western Hospital Healthworks</p> <p>QLD Princess Alexandra</p> <p>WA Fremantle Hospital</p> <p>NT Clinic 34</p> <p>SA Royal Adelaide Hospital</p>
CONTACT PERSON:	Dr Greg Dore or Barbara Yeung (02) 9385 0900